Correlation of antiplatelet agent and statin use with degree of vascular calcification in patients on peritoneal dialysis

초록

Objective: Vascular calcification is a major cause of cardiovascular mortality in patients with end-stage renal disease. Therefore, this study was designed to evaluate whether the use of antiplatelet agents and statins improve vascular calcification and other risk factors in patients undergoing peritoneal dialysis. Design: Retrospective study Setting: Division of Nephrology, Department of Internal Medicine, Inha University Hospital, Republic of Korea Subject: This study included patients with end-stage renal disease who were administered peritoneal dialysis center. Intervention: Medical records of all the patients were reviewed and the data were collected retrospectively. Main outcome measures: The severity and extent of vascular calcification were scored using a semi-quantitative scale ranging from 0 to 8 (Adragao's method). The patient characteristics were compared according to their vascular calcification score. Results: The 156 study patients undergoing peritoneal dialysis had an average vascular calcification score (VCS) of 2.9 +/- 2.7. The VCS was significantly higher in patients with diabetes and increased age but was significantly lower in those prescribed an antiplatelet agent or statin (for >2 years). Patients who used both statins and antiplatelet agents (1.9 +/- 2.4) showed a more significant improvement in vascular calcification than those who used antiplatelet agents alone (3.3 +/- 2.6) or none of the agents (4.2 +/- 2.6) did. In the logistic regression analysis, the statin and antiplatelet agent group showed 0.65 times lower VCS than the control group. Conclusions: Concurrent use of antiplatelet agents and statins decreased vascular calcification in patients undergoing peritoneal dialysis.

키워드